Introduction: The neurotoxic properties of local anesthetics can lead to transient
Introduction
Local anesthetic-induced neurotoxicity is a rare but severe problem. Neurotoxicity of local anesthetics can lead to neurological complications like cauda equina syndrome or transient neurologic syndrome after spinal anesthesia. 1, 2 Lidocaine is the local anesthetic most often linked to local neurotoxicity. 2, 3 Apoptosis has been established as the major mechanism of neurotoxicity by local anesthetics, especially in marginally toxic concentrations. [4] [5] [6] [7] [8] Lidocaine-induced apoptosis is mediated via the mitochondrial pathway independent of death receptor signaling. 7 Similarly, ketamine and midazolam were reported to induce apoptosis by activation of the mitochondrial pathway. 9, 10 Since these substances all induce toxicity via the same pathway, one might presume that toxicities of ketamine and midazolam further enhance the toxicity of lidocaine.
Clinically, intrathecal, epidural and perineural combinations of local anesthetics with adjuvant drugs like opioids, clonidine, epinephrine, neostigmine, ketamine and midazolam are used to improve or prolong neural blockade. [11] [12] [13] Recently, an editorial and a review focusing on pharmacologic adjuvants in single-injection peripheral nerve blocks for patients with diabetes mellitus strongly recommended research regarding injectable analgesic adjuvants for combination with local anesthetics. 14, 15 One important aspect is, that the use of adjuvants might provide the desired analgesia, while reducing the risk of toxicity of local anesthetics. 16 Although at first glance this reasoning seems sensible, there is inadequate safety data on most of these adjuvants. Recently, we demonstrated that lidocaine, ketamine and midazolam all induce apoptosis via the mitochondrial pathway and are toxic in neuronal and glia cells in a concentration-dependent manner. 7 , 9, 10 , 17 Thus, we hypothesized that ketamine and midazolam increase the toxicity of lidocaine at least in an additive manner. Therefore, we screened in our established model of local anesthetic-induced toxicity possible additive toxicity of morphine, sufentanil, clonidine, epinephrine, neostigmine, ketamine and midazolam when added to a toxic concentration of lidocaine.
Since in vivo local anesthetics induce toxicity in neuronal as well as glial cells, 18, 19 we investigated the combination of lidocaine and adjuvants at first in neuronal as well as glial cells in clinically used mixing ratios. Furthermore, to have some margin of safety we investigated the same adjuvants in a tenfold increased concentration than used clinically. Since the primary rodent astrocyte model had steeper dosis-effect curves in investigating combined drug toxicities, this model seems to be more feasible when investigating margins of safety with the tenfold higher adjuvant concentration. For the same reason this model was used to analyse the combined toxicities in a quantitative manner using isobologramms. 20 Hence, the present study focuses on the possible additional toxicity of clinically used adjuvants when combined with lidocaine in neuronal and glial cells.
Material and Methods

Reagents
Preservative-free lidocaine hydrochloride, ketamine hydrochloride and morphine hydrochloride were purchased from Sigma Aldrich in their highest available purity (St.
Louis, MO). Preservative-free clonidine (2-(2,6-dichloroanilino)-2-imidazoline hydrochloride) was purchased from Boehringer Ingelheim (Ingelheim, Germany).
Preservative-free midazolam hydrochloride was provided by Ratiopharm (Ulm, Germany). Epinephrine hydrochloride was obtained from Sanofi-Aventis (Frankfurt, Germany) in a solution containing chlorbutanol and natriummetabisulfate.
Preservative-free sufentanil (Hexal, Holzkirchen, Germany) was used in the highest commercially available concentration and was further diluted with cell culture medium to adjust to desired concentration for experiments. Preservative-free naloxone hydrochloride was purchased from Bristol-Myers Squibb (Anagni, Italy). Roswell Park Memorial Institute (RPMI) 1640 cell culture medium, Dulbecco's modified Eagle medium (DMEM) and phosphate-buffered saline (PBS) without calcium and magnesium were purchased from Gibco, Invitrogen (Carlsbad, CA).
Cell culture
For primary astrocytes, cell preparation was done from cerebral cortices of P2 Wistar rats. After approval of the local Animal Research Committee, rats were anesthetized using Forene® (Abbott, Abbott Park, IL), decapitated, and the brains quickly removed. To avoid fibroblast or endothelial contamination, cortical tissue was carefully isolated from blood vessels and meninges, rinsed with DMEM, dissociated by trypsinization, and suspended in DMEM supplemented with 10% fetal bovine serum (FBS; Invitrogen), penicillin (80 units/mL), and streptomycin (0.2 mg/mL). of ketamine and midazolam alone were described previously in our model. 9, 10 The concentrations of the additives were calculated from those used clinically when coadministred with local anesthetics intrathecally. To have a margin of safety for substances that were not toxic at these initial concentrations the concentrations were increase tenfold. For the substances being toxic with the initial concentrations further concentrations were selected to get an adequate dosis-response curve.
Detection of Early Apoptosis
The fraction of cells in an early state of apoptosis was determined by staining cells with annexin-V and counterstaining with 7-aminoactinomycin (7-AAD). Annexin-V binds to phosphatidylserine on the outer leaflet of the plasma membrane. 7-AAD is excluded by cells with intact membranes. Positive 7-AAD staining is therefore a sign of necrosis, whereas cells positive for annexin-V, but negative for 7-AAD are generally defined as early-apoptotic. All FACS analyses were performed on a FACScalibur (Becton Dickinson, Franklin Lakes, NJ) using CellQuest analysis software (BD Biosciences, Franklin Lake, NJ).
For each determination, a minimum of 10,000 cells were analyzed.
Detection of mitochondrial metabolic activity.
For in vitro determination of mitochondrial viability we used the tetrazolium hydroxide (XTT) assay. XTT, a yellow tetrazolium salt, is cleaved to a soluble orange formazan dye, which can be measured by absorbance. To measure cell viability using XTT, samples were prepared with 100 µL of cell suspension in 96-well cell culture plates and cells were allowed to adhere overnight. Neuroblastoma cells were incubated in a density of 20,000 cells/Well, while primary rat astrocytes were adjusted to 100,000 cells/Well according to their lower metabolic rate. Subsequent to incubation time, 50 µL of XTT assay solution (XTT 1 mg/ml and phenazine methosulfate 50 µM diluted in cell culture medium) were added to each well. Mixing the samples gently for 1 min was followed by incubation for 120 min at 37°C. After additional mixing for 3 min the absorbance was measured spectrophotometrically at a wavelength of 450 nm.
Statistical Analysis
All experiments were performed at least three times. Results are expressed as means ± standard deviation. All calculations were made using the Graph Pad Prism Software version 5.0 (GraphPad Software Inc., La Jolla, CA). Comparisons of effects of drug combinations to those of lidocaine alone were made by one-way analysis of variance (ANOVA) followed by Bonferroni's multiple comparisons post-hoc test. P < 0.05 was considered significant. The calculations of concentration-response relationships and LD50 values were performed with non-linear regression with the log(inhibitor) vs. response mode assuming variable slopes as described before. 17 Resulting equations in the form of [response=bottomvalue+(topvaluebottomvalue)/(1+10^((LogLD50-concentration)*HillSlope))] were used to draw concentration-response slopes and the isobole (± confidence interval 95%) for lidocaine, ketamine, midazolam and the equitoxic combination of lidocaine with both adjuvant drugs. An isobologram is a commonly used method to assess combined drug effects. 20 Therefore, a graph of equally effective dose pairs (isoboles) for a single effect level is drawn. A particular effect level is selected, such as 50% of the maximum (LD 50 ) and concentrations of drug A and B (each alone) that give this effect are plotted as axial points in a Cartesian plot. This graph represents the locus of points (concentration pairs) that lead to a simply additive effect. Experimentally observed concentration pairs which produce this specific effect level can be compared with the line of additivity to discriminate between subadditive, additive and superadditive effects. (Fig. 1) . In contrast, ketamine (2 mM) significantly increased the toxic effect of lidocaine, resulting in observed cell death in 89.7 ± 2.8% of analyzed cells including 14.6 ± 0.6% of cells undergoing early apoptosis (Fig. 1) . Similarly, midazolam (100 µM) induced cell death in 83.7 ± 2.8% of analyzed cells including an early-apoptotic fraction of 26.3 ± 1.5% cells (Fig. 1) . To reconfirm these findings in a primary glial cells carrying all relevant drug targets and functional signaling pathways, another set of experiments was conducted in primary rat astrocytes. These cells were incubated for 24 h with the adjuvants morphine, sufentanil, clonidine, epinephrine and neostigmine at a clinically relevant concentration and a concentration up to 10-times higher to ensure a safety margin. Midazolam and ketamine were co-incubated with lidocaine at concentrations around the margin of toxicity, but well below concentrations as used clinically. As before in SHEP neuroblastoma cells, all investigated adjuvants except ketamine and midazolam did not increase the toxicity of lidocaine (Fig. 2) . Morphine in a high concentration (60 µM) decreased toxicity to a small extent, whereas ketamine and midazolam increased the toxic effect of lidocaine (6 mM; see Fig. 2 ). Co-incubation of morphine (60 µM) for 24 h decreased the toxicity of lidocaine (6 mM) by 21.5 ± 4.2 %. Co-incubation with naloxone hydrochloride in a concentration sufficient to reverse opioid receptor effects (50 µM) did not alter this effect (22.4 ± 3.1% decreased toxicity). Pretreatment with the pan-caspase inhibitor Q-VD (10 µM) significantly increased viability from 44.5 ± 3.1 to 78.7 ± 8.9 % with ketamine (3 mM) and from 78.5 ± 3.4 to 100.9 ± 2.8% with midazolam (100 µM) compared to untreated controls. This indicates that, also in primary astrocytes, apoptosis is the main mechanism of cell death when combined with lidocaine.
Figure 2. Effect of adjuvants on lidocaine-induced apoptosis in primary rat astrocytes.
Clinically relevant and ten times higher concentrations of morphine, sufentanil, clonidine, epinephrine, neostigmine, ketamine and midazolam were coincubated for 24 h with a toxic concentration of lidocaine (6 mM) to screen for additive toxic effects. The concentrations of ketamine and midazolam were chosen around their margin of toxicity. Viability of cells was analyzed by tetrazolium salt (XTT) assay of mitochondrial activity. The dotted line marks the level of mitochondrial activity after treatment with lidocaine without further adjuvants. Ketamine and midazolam decreased cell viability when co-incubated with lidocaine, while all other adjuvants investigated did not increase lidocaine-induced apoptosis. Morphine at a concentration of 60 µM increased mitochondrial activity in lidocaine-treated cells significantly. Data presented as mean and standard deviation. Asterisks indicate significant differences compared to cell treated only with lidocaine (P < 0.05).
In order to investigate the additivity of the toxicity of lidocaine and ketamine as well as lidocaine and midazolam, the concentration-response relationship of all three single compounds was evaluated using the XTT assay for assessment of mitochondrial function and cell viability (Fig. 3) . From these results, concentrationresponse curves and values for half-maximal toxic effects (LD 50 ) were calculated.
Subsequently, isobolograms were established to compare the calculated additive effect with the observed effect of the drug combination. The LD 50 were 7.6 ± 0.2 mM To evaluate the LD 50 of the combined substances, the cells were exposed to increasing fractions (20-80%) of the LD 50 of both substances in combination (Fig. 4) . were incubated in combination with lidocaine using equitoxic concentrations. Therefore, increasing fractions of the calculated LD 50 of each substance were combined to establish a dose-response relationship. For example, 60% of the LD 50 (4.6 mM) of lidocaine and 60% of the LD 50 (4.2 mM) of ketamine led to a reduction of mitochondrial activity by 82.3 ± 3.8%. Each measure point is delineated as mean and standard deviation.
The results were used to calculate the combined LD 50 and were plotted to isobolograms of both combinations (Fig. 5) . The combined LD 50 of lidocaine combined with ketamine was almost precisely on the isobol indicating a pure additive effect. In contrast, the combined LD 50 of lidocaine and midazolam was higher than the upper border of the 95% confidence interval of the corresponding isobol. This indicates a subadditive toxic effect of midazolam when used in combination with lidocaine. Figure 5 . Isobolograms of ketamine and midazolam as adjuvants to lidocaine in primary rat astrocytes. The straight black line connects the LD 50 of lidocaine and ketamine (A) or midazolam (B) resulting in locus of points (dose pairs) that will produce this effect in a simply additive combination. The confidence interval (95%) is represented by the dashed lines. The black data point indicates the calculated halfmaximal concentrations (LD 50 ) resulting from the experimentally observed doseresponse relationship indicated as mean and standard deviation. Note that the experimentally observed effect of equitoxic concentrations of lidocaine and ketamine was within the confidence interval of the predicted effect, indicating an additive effect. In contrast, the combined concentrations of lidocaine and midazolam needed to produce a half-maximal toxic effect were higher than predicted, indicating a subadditive effect.
Discussion
In our in vitro model of lidocaine-induced toxicity on neuronal cells and astrocytes the clinically used adjuvants morphine, sufentanil, clonidine, epinephrine and neostigmine did not alter the toxicity of lidocaine. Morphine in a high concentration had a protective effect that could not be blocked by nalaxone. Contrarily, ketamine increased toxicity in an additive manner and midazolam in a subadditive manner.
Both substances enhanced lidocaine-induced apoptosis and the resulting toxicity could be blocked by a caspase inhibitor.
In the presented study we revealed that ketamine and midazolam increased the neurotoxicity of lidocaine in vitro, whereas the other adjuvants had no toxic effect.
Although the concentrations of lidocaine and the investigated adjuvants may occur only transiently after single shot spinal anesthesia and not over 24 h as in our experiments, maldistribution of the local anesthetics intrathecally may lead to a long exposure of higher concentrations of local anesthetic and subsequent neurological damage. 23 Epinephrine is commonly co-administered as an adjuvant in regional anesthesia as a marker for systemic toxicity or in the intention to induce vasoconstriction and therefore slow the clearance of local anesthetic from the site of injection. 24, 25 Regarding toxicity, epinephrine has been shown to be potentially neurotoxic when used as a adjuvant to local anesthetics neuraxially. 26 Hashimoto and coworkers found an increase of lidocaine-induced neurotoxicity with persistent sensory impairment and histologic damage in rats after intrathecal co-administration with epinephrine, while epinephrine alone did not induce neurotoxicity. 27 The authors therefore presumed that epinephrine-induced vasoconstriction may be the responsible mechanism, leading to a reduction in blood flow and a delayed absorption of lidocaine, hence increasing local anesthetic exposure and toxicity. This might explain the conflicting results of the present study, as effects of vasoconstriction and delayed resorption cannot be adequately simulated in a cell culture model.
Clonidine has been demonstrated to be clinically efficacious in combination with local anesthetics for neuraxial 28 and peripheral nerve block. [29] [30] [31] [32] As with epinephrine, the possible toxicity of clonidine may be related to local vasoconstriction as seen after chronic application and leading to an altered capillary permeability. 33 But in general, clonidine has a well-accepted safety profile for epidural and intrathecal application. 34, 35 In the present study clonidine did not alter toxicity of lidocaine. Again, an in vitro study cannot control for possible effects related to its local vasoconstrictor action.
Opioids are the most commonly used adjuvants for neuraxial blockade. 13, 36 Although many opioids have been used intrathecally and epidurally, we investigating only morphine and sufentanil. These are not only the most often used opioids neuraxially, but also represent a the hydrophilic opioid with low potency and a lipophilic opioid with high potency. The present investigation found no increased lidocaine-induced apoptosis and neurotoxicity after combination with morphine or sufentanil. Although not tested, it seems unlikely that other opioids could increase lidocaine-induced toxicity. Quite the opposite was the case, a high concentration of morphine slightly improved cell viability. Morphine increased mitochondrial activity and thus viability in lidocaine-treated cell cultures. This effect may be related to a general cytoprotective property of morphine. 37, 38 However, sufentanil had no protective effect and the protective effect of morphine could not be blocked by naloxone. Thus, with al likelihood the protective effect of morphine is rather unspecific and unrelated to its action at the opioid receptor. Furthermore, the effect was small and occurred in concentrations far above those used clinically.
Neostigmine, as a cholinesterase inhibitor that produces muscarinic receptormediated analgesia, improves postoperative analgesia when combined with local anesthetics for neuraxial block. 13, [39] [40] [41] [42] Although studies displaying the margins of safety are missing, there are no reports of neurotoxicity so far. In accordance, the present study found no influence of neostigmine on lidocaine-induced apoptosis.
Ketamine, a non-competitive N-methyl-D-aspartate (NMDA) receptor antagonist, is applied epidurally and intrathecally for the treatment of postoperative, chronic cancer pain and neuropathic pain. 43, 44 Ketamine and other NMDA antagonists have been shown to induce neurotoxicity when applied intrathecally over days and weeks. [45] [46] [47] Activation of the mitochondrial pathway of apoptosis was recently demonstrated to be the responsible mechanism for the neurotoxicity of ketamine in vitro.
On the one hand in hundreds of patients no neurotoxiciy was observed, 51 while on the other hand severe neurotoxicity has been described in most animal models of spinal anesthesia. 45, [54] [55] [56] As with lidocaine and ketamine before, we demonstrated that midazolam induces apoptosis via activation of the intrinsic pathway. 10 Therefore, it is not astonishing that midazolam enhances lidocaine-induced apoptosis. In contrast to ketamine this effect was subadditive for unknown reasons.
Ketamine, midazolam and lidocaine all induce toxicity via the same pathway of apoptosis and there is no reason to believe that this toxicity is reserved to neuronal or glia cells. Apoptosis induction of nearly all common local anesthetics has been demonstrated in many different tissues. 7, 8 Thus, synergistic cytotoxicity may also be relevant in any other tissues where toxicity of local anesthetics have been described, i.e. muscle, 57 cartilage 58 and corneal endothelium. 59 Therefore, the injection of socalled analgesic cocktails into different tissues may necessitate more caution than presently given.
Obviously, the cell culture experiments of the presented study have limitations in translating data to the in vivo situation: Human neuroblastoma cells are growing and dividing during the exposure to the investigated substances rather than being mature terminally differentiated neurons. Therefore, primary cell astroglial cell cultures were used in addition. But again, also these primary cells cultures are far away from a clinical situation and the toxic concentrations described here may only be observed for a short time in tissues of patients. Nevertheless, local anesthetic toxicity is rare, but -as it occurs -devastating for the patient. Thus, when searching for additives which may reduce the required dose of local anesthetic to diminish the neurotoxicity, 14 it may be prudent to choose those additives who do not have a record of being neurotoxic in vitro or in vivo.
In conclusion, midazolam and ketamine increase the toxicity of lidocaine and presumably other local anesthetics. Ketamine has an additive toxicity, whereas the effect of midazolam is only subadditive. These synergistic effects may be explained by the same mechanism of action via the mitochondrial pathway of apoptosis of all three substances. Translation of these results to the clinically situation is difficult.
Nevertheless, the co-administration of local anesthetics and midazolam or ketamine may potentially increase their toxicity and further research is needed to clarify indications and margins of safety.
